Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too
In a coda to a six-year legal fight on the PCSK9 terrain, the US Federal Court of Appeals has ruled that Amgen’s patent claims for PCSK9 antibodies as a class are invalid, handing a win to Sanofi and Regeneron.
The implications, though, may reverberate far beyond Amgen.
The Thousand Oaks, CA-based company, whose Repatha was approved a month after Praluent in 2015, may take comfort in the fact that its sales have consistently eclipsed Sanofi or Regeneron’s, although neither has climbed anywhere near the blockbuster expectations developers and analysts had.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
